$83.84
Revenue is up for the last 9 quarters, 402.07M → 602.45M (in $), with an average increase of 4.9% per quarter
Netprofit is up for the last 6 quarters, -220.61M → -74.15M (in $), with an average increase of 26.3% per quarter
In the last 3 years, Idexx Laboratories, Inc. has given 51.8% return, outperforming this stock by 52.9%
1.61%
Downside
Day's Volatility :2.66%
Upside
1.06%
65.09%
Downside
52 Weeks Volatility :65.89%
Upside
2.31%
Period | Exact Sciences Corporation | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 25.08% | 0.9% | -8.3% |
6 Months | 84.06% | -6.8% | -6.5% |
1 Year | 79.57% | 0.4% | -6.1% |
3 Years | -1.13% | 28.3% | 21.8% |
Market Capitalization | 15.1B |
Book Value | $17.0 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -3.0 |
PEG Ratio | -1.07 |
Wall Street Target Price | 86.52 |
Profit Margin | -23.49% |
Operating Margin TTM | -22.87% |
Return On Assets TTM | -4.92% |
Return On Equity TTM | -16.36% |
Revenue TTM | 2.2B |
Revenue Per Share TTM | 12.4 |
Quarterly Revenue Growth YOY | 23.799999999999997% |
Gross Profit TTM | 1.5B |
EBITDA | -303.6M |
Diluted Eps TTM | -3.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.0 |
EPS Estimate Next Year | -1.31 |
EPS Estimate Current Quarter | -0.75 |
EPS Estimate Next Quarter | -0.69 |
What analysts predicted
Upside of 3.2%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 266.0M | ↑ 167.66% |
Net Income | -114.4M | ↓ 31.59% |
Net Profit Margin | -43.01% | ↑ 125.25% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 454.5M | ↑ 70.86% |
Net Income | -175.1M | ↑ 53.11% |
Net Profit Margin | -38.54% | ↑ 4.47% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 876.3M | ↑ 92.82% |
Net Income | -84.0M | ↓ 52.04% |
Net Profit Margin | -9.59% | ↑ 28.95% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.5B | ↑ 70.19% |
Net Income | -848.5M | ↑ 910.24% |
Net Profit Margin | -56.9% | ↓ 47.31% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.8B | ↑ 18.49% |
Net Income | -595.6M | ↓ 29.81% |
Net Profit Margin | -33.71% | ↑ 23.19% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 2.1B | ↑ 17.95% |
Net Income | -623.5M | ↑ 4.68% |
Net Profit Margin | -29.91% | ↑ 3.8% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | 473.8M | ↑ 3.82% |
Net Income | -220.6M | ↑ 32.15% |
Net Profit Margin | -46.56% | ↓ 9.98% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 486.6M | ↑ 2.69% |
Net Income | -180.9M | ↓ 17.98% |
Net Profit Margin | -37.19% | ↑ 9.37% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 521.6M | ↑ 7.21% |
Net Income | -166.1M | ↓ 8.22% |
Net Profit Margin | -31.83% | ↑ 5.36% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 523.1M | ↑ 0.27% |
Net Income | -148.8M | ↓ 10.42% |
Net Profit Margin | -28.44% | ↑ 3.39% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 553.0M | ↑ 5.72% |
Net Income | -127.7M | ↓ 14.13% |
Net Profit Margin | -23.1% | ↑ 5.34% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 602.5M | ↑ 8.94% |
Net Income | -74.2M | ↓ 41.95% |
Net Profit Margin | -12.31% | ↑ 10.79% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 598.6M | ↑ 58.75% |
Total Liabilities | 78.1M | ↑ 87.19% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.5B | ↑ 154.61% |
Total Liabilities | 843.1M | ↑ 978.91% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 3.5B | ↑ 130.03% |
Total Liabilities | 1.2B | ↑ 44.44% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 4.9B | ↑ 40.49% |
Total Liabilities | 2.1B | ↑ 72.59% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 6.7B | ↑ 35.73% |
Total Liabilities | 3.3B | ↑ 56.89% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 6.2B | ↓ 6.85% |
Total Liabilities | 3.2B | ↓ 3.44% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 6.7B | ↑ 0.46% |
Total Liabilities | 3.3B | ↑ 3.14% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 6.5B | ↓ 2.91% |
Total Liabilities | 3.2B | ↓ 1.97% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 6.4B | ↓ 0.82% |
Total Liabilities | 3.2B | ↓ 0.14% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 6.3B | ↓ 2.03% |
Total Liabilities | 3.2B | ↓ 0.93% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 6.2B | ↓ 1.26% |
Total Liabilities | 3.2B | ↓ 0.44% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 6.3B | ↑ 1.24% |
Total Liabilities | 3.2B | ↑ 1.98% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -71.7M | ↓ 44.86% |
Investing Cash Flow | -160.8M | ↑ 1296.0% |
Financing Cash Flow | 261.0M | ↑ 74.45% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -69.3M | ↓ 3.34% |
Investing Cash Flow | -781.9M | ↑ 386.25% |
Financing Cash Flow | 934.1M | ↑ 257.97% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -115.0M | ↑ 65.9% |
Investing Cash Flow | -121.1M | ↓ 84.52% |
Financing Cash Flow | 253.2M | ↓ 72.9% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 136.5M | ↓ 218.67% |
Investing Cash Flow | -702.0M | ↑ 479.85% |
Financing Cash Flow | 1.9B | ↑ 642.4% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -102.2M | ↓ 174.91% |
Investing Cash Flow | -1.1B | ↑ 54.14% |
Financing Cash Flow | 8.5M | ↓ 99.55% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -223.6M | ↑ 118.67% |
Investing Cash Flow | 74.1M | ↓ 106.84% |
Financing Cash Flow | 76.5M | ↑ 802.8% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -24.6M | ↓ 39.74% |
Investing Cash Flow | 78.4M | ↓ 259.29% |
Financing Cash Flow | -12.2M | ↓ 15156.79% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -173.8M | ↑ 607.12% |
Investing Cash Flow | 45.6M | ↓ 41.91% |
Financing Cash Flow | 2.7M | ↓ 122.43% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -60.9M | ↓ 64.94% |
Investing Cash Flow | 21.7M | ↓ 52.46% |
Financing Cash Flow | 63.4M | ↑ 2218.54% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -40.9M | ↓ 32.82% |
Investing Cash Flow | 65.0M | ↑ 200.13% |
Financing Cash Flow | 235.0K | ↓ 99.63% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 52.0M | ↓ 227.15% |
Investing Cash Flow | -58.2M | ↓ 189.47% |
Financing Cash Flow | 10.1M | ↑ 4199.15% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -38.2M | ↓ 173.44% |
Investing Cash Flow | 82.9M | ↓ 242.61% |
Financing Cash Flow | 133.6M | ↑ 1222.34% |
Sell
Neutral
Buy
Exact Sciences Corporation is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Exact Sciences Corporation | 27.51% | 84.06% | 79.57% | -1.13% | 38.44% |
![]() IDEXX Laboratories, Inc. | 0.28% | 11.49% | 26.49% | 51.84% | 115.18% |
![]() Agilent Technologies Inc. | -11.7% | -22.58% | -7.37% | 29.71% | 86.53% |
![]() Thermo Fisher Scientific, Inc. | -4.67% | -6.65% | -5.92% | 49.4% | 142.86% |
![]() Danaher Corp. | -3.18% | -12.45% | -11.04% | 39.0% | 130.31% |
![]() IQVIA Holdings Inc. | 9.2% | -4.98% | -8.8% | 33.17% | 98.9% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Exact Sciences Corporation | NA | NA | -1.07 | -2.0 | -0.16 | -0.05 | 0.0 | 17.0 |
![]() IDEXX Laboratories, Inc. | 55.87 | 55.87 | 7.21 | 9.69 | 0.94 | 0.22 | 0.0 | 10.13 |
![]() Agilent Technologies Inc. | 25.61 | 25.61 | 2.36 | 5.61 | 0.25 | 0.1 | 0.01 | 19.6 |
![]() Thermo Fisher Scientific, Inc. | 28.81 | 28.81 | 4.28 | 23.68 | 14.48 | 0.05 | 0.0 | 109.55 |
![]() Danaher Corp. | 25.07 | 25.07 | 3.24 | 9.38 | 0.14 | 0.06 | 0.0 | 68.31 |
![]() IQVIA Holdings Inc. | 36.24 | 36.24 | 1.48 | 10.42 | 0.18 | 0.05 | 0.0 | 31.98 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Exact Sciences Corporation | Buy | $15.1B | 38.44% | NA | -23.49% |
![]() IDEXX Laboratories, Inc. | Buy | $39.0B | 115.18% | 55.87 | 20.38% |
![]() Agilent Technologies Inc. | Buy | $34.3B | 86.53% | 25.61 | 19.19% |
![]() Thermo Fisher Scientific, Inc. | Buy | $200.3B | 142.86% | 28.81 | 13.75% |
![]() Danaher Corp. | Buy | $171.7B | 130.31% | 25.07 | 22.4% |
![]() IQVIA Holdings Inc. | Buy | $36.9B | 98.9% | 36.24 | 7.28% |
Vanguard Group Inc
ARK Investment Management LLC
BlackRock Inc
Wellington Management Company LLP
JPMorgan Chase & Co
Capital World Investors
Exact Sciences Corporation’s price-to-earnings ratio stands at None
Read MoreA leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.
Organization | Exact Sciences Corporation |
Employees | 6300 |
CEO | Mr. Kevin T. Conroy |
Industry | Health Technology |
Zimmer Biomet Holdings, Inc.
$129.81
+1.92%
Mettler-Toledo International Inc.
$1,332.66
+0.25%
United Therapeutics Corporation
$217.22
+1.75%
Edwards Lifesciences Corp.
$85.34
+0.13%
AmerisourceBergen Corp.
$174.52
+1.12%
Molina Healthcare, Inc.
$287.17
+1.48%
GE HEALTHCARE TECHNOLOGIES INC.
$79.97
+0.18%
Cigna Corp.
$257.03
+1.44%
IQVIA Holdings Inc.
$201.37
+1.21%